ClinicalTrials.gg
CompletedNCT04857268Updated Nov 18, 2026

Diagnostic Validation of Wearable ECG Monitoring Patch, ATP-C120

An interventional study of wearable continuous ECG monitoring patch, ATP-C120 in Atrial Fibrillation New Onset, sponsored by Seoul National University Bundang Hospital. Completed at 2 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionAtrial FibrillationRegistry: Arrhythmias, CardiacReclassifiedWhy we changed it
Registry
Arrhythmias, Cardiac — the first condition term the registry derived for this study.
ClinicalTrials.gg
Atrial Fibrillation
Why
  1. The study's listed conditions name Atrial Fibrillation, a narrower term within Arrhythmias, Cardiac.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Seoul National University Bundang Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2020, registered Apr 2021).
Updated Nov 18, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 209 studies in Atrial Fibrillation with a site in Korea, Republic of — 61 open to participants now, 69 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Enrollment
69th of 144
320 · median 300
Started
2020
with 11 others
No phase
91 of 209
36 open now
Registered
131st of 209
by date

Among the 209 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 69th largest by enrollment of the 144 interventional ones that give a count, is one of 12 that started in 2020, is one of 91 with no phase, and was the 131st registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

61 of the 209 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A new wearable patch-type device, ATP-C120 (ATsens, Seongnam, Korea) is a novel, single-lead ECG monitoring device and can continuously monitor the ECG signal for upto 11 days. This study is designed to experiment its diagnostic capability of new-onset atrial fibrillation in high risk patients. Several studies reported that validated CHA2DS2-VASc score has high performance in predicting new-onset atrial fibrillation and there are over 10 percent of new-onset atrial fibrillation in patients whose calculated CHA2DS2-VASc scores are ≥ 2. Thus, through this study, the investigators sought to evaluate the validation of early detection of new-onset atrial fibrillation by ATP-C120.

Read the detailed description

The prevention of stroke associated with atrial fibrillation is a leading global health concern. This devastating event is largely preventable with anticoagulant therapy. Therefore, the early detection and accurate diagnosis of arrhythmia are crucial for prevention of adverse outcome. However, because atrial fibrillation is often intermittent and mostly asymptomatic, it is difficult to capture an excise event.

Conventional electrocardiogram (ECG) monitoring devices including multi-lead portable ECG monitoring device, event-detection monitoring device, and implantable ECG monitoring device are useful for early detection of atrial fibrillation, but these devices have various drawbacks such as requirement of multiple out-patient visits and need of invasive implantation of devices.

A new wearable patch-type device, ATP-C120 (ATsens, Seongnam, Korea) is a novel, single-lead ECG monitoring device and can continuously monitor the ECG signal for upto 11 days. It has recently demonstrated its diagnostic capability and safety compared to the conventional ECG monitoring systems . Yet, it has not widely used in real-world. So, this study is designed to experiment its diagnostic capability of new-onset atrial fibrillation in high risk patients. Several studies reported that validated CHA2DS2-VASc score has high performance in predicting new-onset atrial fibrillation and there are over 10 percent of new-onset atrial fibrillation in patients whose calculated CHA2DS2-VASc scores are ≥ 2. Thus, through this study, the investigators sought to evaluate the validation of early detection of new-onset atrial fibrillation by ATP-C120.

03

Conditions studied

  • Atrial Fibrillation New Onset

Browse trials for

Keywords

  • Arrhythmia
  • Atrial Fibrillation
  • Wearable Electronic Device
04

In context

Atrial Fibrillation Reclassified

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

This study's enrollment of 320 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Seoul National University Bundang Hospital is the lead sponsor of 377 studies on the registry; 56 are open to participants now.

Compared within Atrial Fibrillation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arrhythmias, Cardiac. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. patients who provide written and to participate
  2. patients whose calculated CHA2DS2-VASc score is ≥ 2

Exclusion criteria

Exclusion Criteria:

  1. subjects previously diagnosed with atrial fibrillation
  2. subjects implanted pacemaker, cardioverter-defibrillator, or any electrical devices
  3. subjects had skin problems such as allergic contact dermatitis
  4. female patients who are pregnant, or lactating status.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    ATP-C120 application

    ATP-C120 will be applied to the high patients for new-onset atrial fibrillation

    Device: wearable continuous ECG monitoring patch, ATP-C120

Interventions

  • Devicewearable continuous ECG monitoring patch, ATP-C120

    ATP-C120 is a novel, single-lead ECG monitoring device which can continuously monitor the ECG signal as long as 14 days (11 days if the device is connected to the smartphone via Bluetooth) when attached to skin adjacent to the heart of patients. It weighs about 8.3 g, with a size of 84 × 39 × 8.3 mm. When the device is attached to the patient, several predefined methods were utilized to prevent the occurrence of noise or signal loss. First, the skin was cleansed and disinfected using a 70% ethanol solution. Skin hair was removed if needed. Then the protection film was removed from the patient-side surface of the device. The device is placed at the left 3rd intercostal space 45 degrees tilted toward the inside.

07

What researchers measure

Primary outcomes

  1. Rate of new-onset atrial fibrillation

    new-onset atrial fibrillation recognized by ATP-C120 patch device

    Time frame: 11 days

Secondary outcomes

  1. Rate of new-onset atrial fibrillation

    new-onset atrial fibrillation recognized by conventional ECG monitoring device

    Time frame: 6 month

08

Study locations

2 sites
  • Seoul National Universtiy Bundang Hospital
    Seongnam-si, Gyeonggi-do 463-707, South Korea
  • Kyungpook National University Hospital
    Daegu, South Korea
09

References and documents

Publications

  • Choi W, Kim SH, Lee W, Kang SH, Yoon CH, Youn TJ, Chae IH. Comparison of Continuous ECG Monitoring by Wearable Patch Device and Conventional Telemonitoring Device. J Korean Med Sci. 2020 Nov 16;35(44):e363. doi: 10.3346/jkms.2020.35.e363. PubMed 33200590 ↗
  • Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77. doi: 10.1056/NEJMoa1311376. PubMed 24963566 ↗
  • Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5. doi: 10.1001/jama.285.18.2370. PubMed 11343485 ↗
  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67. doi: 10.7326/0003-4819-146-12-200706190-00007. PubMed 17577005 ↗
  • Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015 Apr;17(4):507-8. doi: 10.1093/europace/euv041. No abstract available. PubMed 25833879 ↗
  • Waks JW, Buxton AE. Risk Stratification for Sudden Cardiac Death After Myocardial Infarction. Annu Rev Med. 2018 Jan 29;69:147-164. doi: 10.1146/annurev-med-041316-090046. PubMed 29414264 ↗
  • Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012 Jan 12;366(2):120-9. doi: 10.1056/NEJMoa1105575. PubMed 22236222 ↗
  • Camm AJ, Corbucci G, Padeletti L. Usefulness of continuous electrocardiographic monitoring for atrial fibrillation. Am J Cardiol. 2012 Jul 15;110(2):270-6. doi: 10.1016/j.amjcard.2012.03.021. Epub 2012 Apr 12. PubMed 22503584 ↗
  • Kwun JS, Lee JH, Park BE, Park JS, Kim HJ, Kim SH, Jeon KH, Cho HW, Kang SH, Lee W, Youn TJ, Chae IH, Yoon CH. Diagnostic Value of a Wearable Continuous Electrocardiogram Monitoring Device (AT-Patch) for New-Onset Atrial Fibrillation in High-Risk Patients: Prospective Cohort Study. J Med Internet Res. 2023 Sep 18;25:e45760. doi: 10.2196/45760. PubMed 37721791 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2022, 17 months.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's 17 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2022 → Apr 2022 and completion Dec 2023 → Apr 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 23, 2021
StartActual
Nov 13, 2020
Primary completionActual
Apr 30, 2022was Dec 2022
CompletionActual
Apr 30, 2023was Dec 2023
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 18, 2026
Sites
1 site added, 1 site removed
Show site
  • Seoul National Universtiy Bundang Hospital · Seongnam-si, South Korea
Show 1 removed
  • Seoul National Universtiy Bundang Hospital · Seongnam, Korea, Republic of
Nov 18, 2026
Primary completion
Dec 31, 2022→Apr 30, 2022 (actual)
Nov 18, 2026
Study completion
Dec 31, 2023→Apr 30, 2023 (actual)
Nov 18, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37721791 ↗
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37721791 ↗
    1 site added, 1 site removed
    Show site
    • Seoul National Universtiy Bundang Hospital · Seongnam-si, South Korea
    Show 1 removed
    • Seoul National Universtiy Bundang Hospital · Seongnam, Korea, Republic of
    Primary completion Dec 31, 2022→Apr 30, 2022 (now actual)
    Study completion Dec 31, 2023→Apr 30, 2023 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04857268
Collaborators
Kyungpook National University Hospital
Responsible party
Chang-Hwan Yoon (Professor, Seoul National University Bundang Hospital) — Principal investigator
First posted
Apr 23, 2021
Start date
Nov 13, 2020
Primary completion
Apr 30, 2022
Completion
Apr 30, 2023
Last update
Nov 18, 2026

Study contacts

Chang-Hwan Yoon, MD.,Ph.D.
principal investigator · Seoul National University Bundang Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion